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Abstract
The polycomb group protein enhancer of zeste homologue 2 (EZH2), which has histone methyltransferase (HMT)
activity, is overexpressed in malignant tumours. However, the role of EZH2 in colorectal cancer (CRC) invasion is
little known. Here we investigated the clinical significance, biological effects, and mechanisms of EZH2 signalling.
Knockdown of EZH2 significantly reduced cell invasion and secretion of matrix metalloproteinases 2/9 (MMP2/9)
in in vitro studies. Knockdown of EZH2 dramatically increased overall survival and decreased metastasis of lung in
in vivo studies. Conversely, overexpression of EZH2 significantly increased lung metastasis and shortened overall
survival when compared with control tumours. EZH2-induced CRC cell invasion may depend on down-regulation
of vitamin D receptor (VDR), which is considered to be a marker of CRC invasion. EZH2 regulates the histone
trimethylation of lysine 27 (H3K27me3) in the VDR promoter. Moreover, we found that STAT3 directly binds
to the EZH2 promoter and regulates VDR down-regulation in CRC cells. Significant inverse correlations were
observed between the expression of EZH2 and pSTAT3 and that of VDR in CRC tissues compared with normal
tissue in patients. We show the role of EZH2 in CRC metastasis and identify VDR as a target gene of EZH2. EZH2
expression may be directly regulated by STAT3, and STAT3 may play an important role in EZH2-mediated VDR
down-regulation in CRC. This pathway may provide potential targets in aggressive CRC.
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Introduction
Although colorectal cancer (CRC) mortality has
decreased in the past decade, it remains a leading
cause of morbidity and mortality [1,2]. Genetic and
epigenetic alterations are important in the pathogenesis
of CRC [3–5]. In addition to well-defined promoter
DNA hypermethylation and histone deacetylation,
deregulation of polycomb-induced gene silencing has
been reported [6–8]. The enhancer of zeste homologue
2 (EZH2 ) protein is a core component of the poly-
comb repressive complex 2 (PRC2), which modifies
transcription at the epigenetic level by affecting both
histone and DNA methylation [9]. Recent studies
have shown that EZH2 silences tumour suppressor
gene expression, via the modification of lysine 27 in
H3 histone tails in the promoter region of the target
gene [10,11]. Overexpression of EZH2 correlates with
invasiveness in several cancers [12,13] but the role of
EZH2 in the invasion of CRC remains unclear.
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As a member of the steroid hormone receptor
superfamily, the vitamin D receptor (VDR) regulates
gene expression in a ligand-dependent manner [14].
VDR was initially isolated from the nuclei of chicken
small intestinal cells [15]. The active metabolite of
vitamin D, 1α,25-dihydroxyvitamin D3, induces the
expression of E-cadherin, which plays a causal role in
the invasion of carcinoma cells that express the VDR
[16,17]. Aggressive CRC cells with a high metastatic
potential have low levels of VDR expression [18].
In addition, snail2 and snail1, the inducers of CRC
cell invasion, may cooperate to repress expression of
the VDR in CRC [19].Therefore, down-regulation of
the VDR may be involved in the pathogenesis of
CRC and could be a predictive marker of malignant
potential [20].
Overexpression of EZH2 is associated with a poor
outcome [21]. It has been reported that the mitogen-
activated protein kinase (MAPK) pathway regulates
EZH2 overexpression in subtypes of aggressive breast
cancer [22]. The expression and function of EZH2
may be regulated by microRNA [23] and non-coding
RNA [24]. However, the mechanism by which EZH2
is overexpressed in CRC remains unclear.
Accumulating evidence indicates that abnormalities
in the Janus kinase/signal transducer and activator of
transcription (JAK/STAT) pathway are involved in the
oncogenesis of CRC [25,26]. As a key component
of the JAK/STAT pathway, STAT3 is constitutively
activated in CRC [27]. Yeh et al . postulated that
EZH2 may be regulated by STAT3 in prostate cancer
[28]. Furthermore, EZH2 has been shown to regulate
VDR gene expression in germinal centre B cells [29].
Whether EZH2 mediates VDR expression and the
transcription factor(s) responsible for overexpression
of EZH2 in CRC cells is not known. Our goal was to
investigate this hypothesis.
Materials and methods
Cell culture and treatment
Human colon cancer cell lines HT29, SW1116,
HCT116, and SW620 (ATCC, Manassas, VA, USA)
were maintained in 1640 medium (Gibco, Carls-
bad, CA, USA), respectively, supplemented with
10% fetal bovine serum (FBS). CRL-1790 cells, a
‘normal’ human colon epithelial cell line (ATCC),
were also used. CRL-1790 cells were grown in F-12
medium enriched with 0.02 mg/ml insulin, 0.01 mg/ml
transferrin, 25 nM sodium selenite, 50 nM hydrocor-
tisone, 1 ng/ml epidermal growth factor, 0.01 mM
ethanolamine, 0.01 mM phosphorylethanolamine,
100 pM triiodothyronine, 0.5% (w/v) bovine serum
albumin, 10 mM HEPES, 0.5 mM sodium pyruvate,
and an extra 2 mM L-glutamine (final concentration
4.5 mM). Cell density was maintained at approximately
100 000 cells per millilitre of medium. Cells were
then plated in fibronectin- and collagen type I-coated
T-25 flasks. All of the cells were incubated at 37 ◦C
in a humidified 5% CO2 atmosphere.
Immunohistochemical staining
All specimens (tumour and parallel normal) were
obtained from 129 patients with primary CRC, who
underwent surgery at the Shanghai Renji Hospital from
July 2009 to May 2012. All patients provided written
informed consent before enrolment, and the study pro-
tocol was approved by the Ethics Committee of Shang-
hai Jiao-Tong University School of Medicine, Renji
Hospital. The study was carried out according to the
provisions of the Helsinki Declaration of 1975. None
of the patients received pre-operative treatment. The
expression levels of pSTAT3, STAT3, EZH2 , and VDR
were examined with primary antibodies (STAT3, dilu-
tion 1 : 100; pSTAT3, EZH2 , and VDR, dilution 1 : 50)
using the LSAB + kit (DakoCytomation, Copenhagen,
Denmark) according to the manufacturer’s instructions.
Antibodies used in this study were purchased from Cell
Signaling Technology Inc (Beverly, MA, USA).
The slides were examined independently by two
investigators, who were blinded to the clinical and
pathological data. Protein expression was quantified
using a visual grading system based on the extent and
intensity of staining (percentage of positive tumour
cells was graded on a scale of 0–4: 0, none; 1,
1–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%) and
the intensity of staining (graded on a scale of 0–3: 0,
no staining; 1, weak staining; 2, moderate staining; 3,
strong staining). For further analysis, an index value
was calculated as a product of the grades of the extent
and intensity of staining to define the cut-off value for
high expression of the proteins, and protein expression
was classified into two categories: high (grades 4–12)
and low (grades 0–3).
Animal experiments
We developed a CRC metastasis model in nude mice.
HCT116 cells were infected with lenti-GFP-control
virus to construct HCT116-GFP-control stable cell
lines. HCT116 cells and HCT116-GFP-control stable
cells (2.5 × 106) were suspended in 500 µl of PBS
and injected through the tail veins of 6-week-old nude
mice [30]. Forty days later, the NightOWL II LB 983
in vivo imaging system (Berthold Technologies, Bad
Wildbad, Germany) was used to image the metas-
tases. Preliminary data showed that GFP-positive sub-
cutaneous metastasis was successfully detected after
the injection of HCT116-GFP-control stable cells, but
almost no GFP-positive subcutaneous metastasis was
detected after the injection of PBS or HCT116 cells.
All of the lentiviruses were provided by Shanghai Sun-
bio Biomedical Technology (Shanghai, China).
SW1116 cells were infected with lenti-GFP-EZH2
virus or lenti-GFP-control virus and HCT116 cells
were infected with lenti-GFP-EZH2 shRNA virus
or lenti-GFP-control shRNA virus to construct the
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SW1116-GFP-EZH2 , SW1116-GFP-control, HCT116-
GFP-shEZH2, and HCT116-GFP-control shRNA sta-
ble cell lines, respectively. We injected PBS, SW1116
cells, SW1116-GFP-control cells, SW1116-GFP-EZH2
cells, HCT116 cells, HCT116-GFP-control shRNA
cells or HCT116-GFP-shEZH2 cells into the tail veins
of nude mice once a week. At 40 days, photographs
were taken with the NightOWL II LB 983 imaging sys-
tem. During this time, we recorded the survival time
of the nude mice and survival curves were generated.
The livers and lungs of the nude mice were excised
post-mortem for haematoxylin and eosin staining [31].
Details of the CRC xenograft animal models may be
found in the Supplementary methods. All experimental
procedures were approved by the Institutional Animal
Care and Use Committee.
Chromatin immunoprecipitation (ChIP) and
real-time ChIP
ChIP assays were performed using the ChIP assay
kit (Upstate, Charlottesville, VA, USA) according to
the manufacturer’s instructions. The protein–DNA
complexes were precipitated using 5 µg of antibod-
ies against trimethyl-histone 3-Lys27 (3meH3K27;
#07–449, BD San Jose, CA, USA), STAT3 (#9132,
CST), EZH2 (#4905, CST, San Jose, CA, USA) or
IgG control (#12–370, Santa Cruz, Dallas, TX, USA).
Approximately 2–5 µl of ChIP-enriched chromatin was
subjected to a standard ChIP–PCR reaction, and the
enrichment of specific genomic regions was assessed
relative to either control IgG or control cells.
Real-time PCR was performed using an Applied
Biosystems 7900 quantitative PCR system. Each
PCR reaction was carried out in a 10 µl reaction
volume using 3 µl of the eluted immunoprecip-
itated DNA. The amount of genomic DNA that
co-precipitated with the specific antibody was
calculated in comparison to the total input DNA
used for each immunoprecipitation as follows:
CBTB = CBTB(genomic input) − CBTB(specific
antibody), where CBTB(genomic input) and
CBTB(specific antibody) are the mean thresh-
old cycles of PCR performed in triplicate on
DNA samples from the genomic input samples
and the specific antibody samples, respectively.
The ChIP primers for the VDR gene promoter
were VDR-F (5′-CCCTTGGGTGAGATT-3′) and
VDR-R (5′-CTCCGCACGAATGG-3′). The ChIP
primers for the EZH2 gene promoter were EZH2 -F
(5′-GGCGTCCTGTTGAA-3′) and EZH2 -R (5′-
CCGCCAACAAACTG-3′; Figure 6C). A ChIP primer
pair for GAPDH was used as a negative control for
STAT3 binding: (5′-CACCGTGTGCCCAAGACCTC-
3′) and (5′-CAGCCCTGTAGCCTGGACCT-3′).
Statistical analysis
Statistical analysis was performed with SPSS 13.0 soft-
ware (SPSS Inc, Chicago, IL, USA). For clinicopatho-
logical analysis, the chi-squared test or Fisher’s exact
test (two-sided) was performed. The Kaplan–Meier
method was used to estimate the overall survival,
and the log-rank test was used to evaluate the dif-
ferences between survival curves. Correlation analyses
were performed for the expression of pSTAT3, STAT3,
EZH2 , and VDR. Statistical tests and p values were
two-sided. Results were considered significant if the p
value was less than 0.05.
Results
Expression of EZH2 in CRC tissues and cells
As shown in Figure 1A, EZH2 staining was mainly
detected in the nuclei of cells in CRC tissue sam-
ples, with almost no EZH2 staining observed in nor-
mal epithelial tissues. Furthermore, the expression of
EZH2 was much higher in tissues from CRC patients
with metastasis than in those without metastasis. We
found an association between EZH2 expression and
several known clinicopathological features in CRC.
EZH2 expression was positively correlated with loca-
tion, TNM stage, histological grade, vascular invasion,
and lymph node metastasis (Supplementary Table 1).
Western blot analysis (Figure 1B) showed that EZH2
was not detectable in normal human colon epithelial
cells (CRL-1790), but EZH2 expression was signifi-
cantly increased in all of the CRC cell lines tested,
especially in highly invasive CRC cells.
EZH2 plays an important role in CRC cell invasion
EZH2 may mediate cell proliferation and invasion
in human cancers [8,32,33]. To study this in CRC,
first, we introduced lenti-EZH2 shRNA-1/2 viruses
or a lenti-EZH2 overexpression virus into CRC
cells. Lenti-EZH2 shRNA-1/2 viruses successfully
decreased EZH2 expression, respectively (Supple-
mentary Figure 1A). Moreover, introduction of the
lenti-EZH2 overexpression virus remarkably increased
EZH2 expression (Supplementary Figure 1B). There
was no significant change of EZH2 expression after
transduction of the control shRNA or control viruses
when compared with control CRC cells.
In Transwell cell invasion assays, representative data
showed that knockdown of EZH2 expression signif-
icantly reduced the invasion ability of CRC cells
(Figure 1C). Moreover, overexpression of EZH2 dra-
matically increased the invasion ability of CRC cells
(Figure 1C), indicating that EZH2 may have a sig-
nificant effect on cell migration and invasion in CRC
cells. In wound healing assays, less wound closure
was observed in CRC cells with knockdown of EZH2
compared with control. Furthermore, more wound clo-
sure was observed in CRC cells with overexpression of
EZH2 compared with control (Figure 1D). This result
was further confirmed by ELISA assays, as knockdown
of EZH2 significantly reduced the secretion of MMP2
and MMP9 in CRC cells (Supplementary Figure 2).
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Figure 1. Expression and function of EZH2 in CRC tissues and cells. (A) Immunohistochemical analysis of EZH2 in normal colorectal
mucosa, CRC tissues, and CRC tissues from patients with metastasis (original magnification ×400). (B) Western blot analysis showing
almost no expression of EZH2 in a normal human colon epithelial cell line, CRL-1790; however, the expression of EZH2 was significantly
increased in all CRC cell lines, especially in highly invasive CRC cells. (C) Transwell Matrigel invasion assays were performed in CRC cells
infected with control shRNA or EZH2 shRNA viruses or control or EZH2 overexpression virus. Cells were observed under a light microscope
and photographed. Cells were counted from five random microscopic fields (200×) per insert in triplicate. The migrated cell numbers were
normalized to that of the control group. Data are shown as mean ± SD from three separate experiments. (D) Wound healing assays were
performed in CRC cells after infection with the EZH2 overexpression virus, control virus, control shRNA virus or EZH2 shRNA virus. n = 3,
ANOVA,*p < 0.05, compared with CRL-1790 cells; n= 3, ANOVA, p< 0.05, compared with the control shRNA virus; n= 3, p< 0.05
(Student’s t test).
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We then explored the functional impact of EZH2
overexpression/knockdown. Different stable cells were
transplanted into BALB/c-nu/nu mice via tail vein
injection. Increased numbers of subcutaneous metas-
tases were detected after injection of SW1116-GFP-
EZH2 cells, compared with mice injected with con-
trol cells (Figure 2A). Mice inoculated with SW1116-
GFP-EZH2 cells had a shorter overall survival time
(mean 65.7 days) compared with those injected with
control cells (mean 76.4 days; Figure 2C). Haema-
toxylin and eosin staining showed that fewer metastatic
CRC cells were observed in the lungs of nude mice
at 17 weeks after injection of SW1116-GFP-control
cells, while most of the mice injected with SW1116-
GFP-EZH2 cells displayed significant lung metastases
(Figure 2E and Supplementary Table 2). Fewer subcu-
taneous metastases were detected after down-regulation
of EZH2 (Figure 2B). Knockdown of EZH2 remark-
ably increased the overall survival time and signifi-
cantly decreased lung metastasis of tumour cells in vivo
(Figures 2D, 2E, and Supplementary Table 2). These
data suggest that EZH2 expression plays a critical role
in CRC cell motility and metastasis.
We compared the survival time in patients with
EZH2 -expressing tumours (n = 17) with that of patients
with EZH2 -negative tumours (n = 16; Figure 2F). The
cumulative survival rate was significantly better in
patients with EZH2 -negative tumours than in those
with EZH2 -positive tumours (p< 0.05, HR = 0.1973,
95% CI 0.06–0.66), indicating that EZH2 overexpres-
sion is significantly associated with patient survival in
CRC.
EZH2 negatively regulates VDR expression in CRC
cells and EZH2-induced CRC cell invasion depends
on the repressing of VDR
E-cadherin expression is regulated by EZH2 via the
histone methylation of E-cadherin promoter [34,35].
Velichutina et al . predicted that VDR is a target
of EZH2 [29]. We examined whether EZH2 regu-
lates VDR expression in CRC cells. Real-time PCR
data showed that up-regulation of EZH2 significantly
down-regulated VDR expression in SW1116 cells
(Figures 3A and 3C). Conversely, down-regulation
of EZH2 significantly increased the mRNA level
(Figure 3B) and protein levels (Figure 3D) of VDR in
HCT116 cells. The data suggest that EZH2 may regu-
late VDR expression in CRC cells. In addition, over-
expression of VDR significantly decreased the inva-
sion ability of CRC cells under basal conditions. Up-
regulation of VDR blocked EZH2 -induced cell inva-
sion in SW1116 cells (Figure 3E) and down-regulation
of VDR restored the EZH2 shRNA-induced decrease
in cell invasion ability in HCT116 cells (Figure 3F),
indicating that EZH2 -induced CRC cell invasion may
depend on the suppression of VDR expression.
To explore the mechanism of EZH2 -induced VDR
down-regulation in CRC cells, we constructed a
luciferase reporter plasmid containing part of the VDR
promoter region. Knockdown of EZH2 significantly
increased the transcriptional activity of the VDR pro-
moter in HCT116 cells (Figure 4A), indicating that
EZH2 may mediate VDR expression by regulating
the transcriptional activity of the VDR promoter. We
then examined the H3K27 methylation level of the
VDR promoter after knockdown of EZH2 . As shown
in Figure 4B, VDR genomic DNA was detectable in
a ChIP assay when either an H3K27me3 antibody
or EZH2 antibody was used, and Figure 4C shows
that knockdown of EZH2 significantly decreased the
H3K27 histone methylation level of the VDR promoter,
suggesting that EZH2 may regulate the expression of
VDR by modulating the H3K27 histone trimethylation
in the VDR promoter region.
Supplementary Tables 1 and 4 show the frequencies
of EZH2 and VDR expression in 129 paired samples
of normal and CRC tissues from patients undergo-
ing colorectal surgery. In consecutive tissue sections
(Figure 4D), EZH2 was expressed at higher levels in
the CRC samples than in the control tissues. In con-
trast, VDR was expressed at lower levels in the tumour
tissues than in the normal colon epithelial samples. Our
data suggest that EZH2 is significantly up-regulated in
CRC (chi-squared test, p< 0.0001), while VDR is sig-
nificantly down-regulated (chi-squared test, p = 0.012).
Additionally, the expression levels of EZH2 and VDR
were inversely correlated (Spearman’s correlation coef-
ficient r = −0.65720; p< 0.0001).
STAT3 regulates EZH2 expression in CRC cells
STAT3 mediates the invasion of cancer cells [36,37].
Since EZH2 mediates CRC cell invasion and EZH2-
induced CRC cell invasion depends on the suppres-
sion of VDR expression, we next determined whether
STAT3 regulates the expression of EZH2 and VDR in
CRC cells. Western blot analysis showed that knock-
down of STAT3 significantly decreased EZH2 expres-
sion and increased VDR expression in CRC cells
(Figures 5A and 5B). Moreover, EZH2 expression was
markedly increased and VDR expression was signif-
icantly decreased after overexpression of STAT3 in
CRC cells (Figures 5C and 5D), suggesting that STAT3
may play an important role in EZH2 up-regulation and
VDR down-regulation. Knockdown of EZH2 blocked
STAT3-induced down-regulation of VDR expression
levels in CRC cells (Figures 5E and 5F), indicating
that STAT3-mediated VDR down-regulation depends
on the activation of EZH2 .
To explore the mechanism of STAT3-induced EZH2
up-regulation in CRC cells and based on our pre-
liminary luciferase reporter gene data (Supplementary
Figure 3), we constructed a luciferase reporter plas-
mid containing part of the EZH2 promoter region
(from −420 to +80 nt). Overexpression of STAT3 dra-
matically increased the transcriptional activity of the
EZH2 promoter in HCT116 cells (Figure 6A). More-
over, DNA sequence analysis of the EZH2 promoter
region revealed six putative STAT3 binding sites. The
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Figure 2. Functional impact of EZH2 overexpression/knockdown on the metastatic potential of CRC cells in vivo. (A) Assessment of the
subcutaneous metastatic capacity of 2.5 × 106 SW1116-GFP-control or SW1116-GFP-EZH2 cells after inoculating nude mice via tail
vein injection. Biofluorescence images and summarized data show subcutaneous metastasis and total photon flux for each treatment
group (a: mice injected with PBS; b: mice injected with SW1116-GFP-control stable cells; c: mice injected with SW1116-GFP-EZH2
stable cells). n = 15, ANOVA, *p < 0.0001. (B) Assessment of subcutaneous metastatic capacity of 2.5 × 106 HCT116-GFP-control
shRNA or HCT116-GFP-shEZH2-1/2 tumour cells by inoculating nude mice via tail vein injection. Biofluorescence images and summarized
data show subcutaneous metastasis and total photon flux for each treatment group (d: mice injected with PBS; e: mice injected with
HCT116-GFP-control shRNA stable cells; f1: mice injected with HCT116-GFP-shEZH2-1 stable cells; f2: HCT116-GFP-shEZH2-2 stable
cells). n = 15, ANOVA, *p< 0.0001. (C, D) Survival curves for mice. n = 15, **p< 0.05 (Student’s t-test), compared with SW1116-GFP-control
cells or HCT116-GFP-control shRNA cells. (E) Increased numbers of metastatic CRC cells were detected in the lungs of nude mice at
17weeks after the injection of the SW1116-GFP-EZH2 group compared with the SW1116-GFP-control group. Fewer metastatic CRC cells
were detected in the lungs of nude mice injected with HCT116-GFP-shEZH2-1/2 cells at 17weeks compared with mice injected with
HCT116-GFP control shRNA cells.(F) Survival analysis showed that EZH2-positive tumours have an unfavourable prognosis compared with
EZH2-negative tumours in patients (p < 0.05, HR = 0.1973, 95% CI 0.06–0.66).
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Figure 3. Role of EZH2 in VDR regulation and effect of VDR on EZH2-induced CRC cell invasion. (A) Real-time PCR data show that
infection of EZH2 overexpression virus dramatically increased EZH2 mRNA expression and decreased VDR mRNA expression in SW1116
cells. n = 3, *p < 0.01 (Student’s t-test). (B) Real-time PCR show that EZH2 shRNA virus significantly decreased the mRNA level of the
EZH2 gene and increased the mRNA level of the VDR gene in HCT116 CRC cells. n = 3, **p < 0.01 (Student’s t-test). (C)Western blot
analysis data show that overexpression of EZH2 significantly decreased the expression of VDR in SW1116 cells. n = 3, *p < 0.01 (Student’s
t-test). (D) Knockdown of EZH2 dramatically increased the expression of VDR in HCT116 cells. n = 3, **p < 0.01 (Student’s t-test). (E, F)
Transwell Matrigel invasion assays were performed in CRC cells infected with different viruses as indicated. Cells were observed under a
light microscope and photographed. Cells were counted from five random microscopic fields (200×) per insert in triplicate. The migrated
cell numbers were normalized to that of the control group. Data are shown as mean ± SD from three separate experiments. n = 3, ANOVA,
p < 0.01, compared with control; p < 0.05, compared with EZH2 overexpression virus or EZH2 shRNA virus.
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Figure 4. The mechanism of EZH2-mediated VDR down-regulation in CRC cells. (A) Knockdown of EZH2 significantly increased the
luciferase activity of the VDR gene promoter. n = 3, *p = 0.0005 (Student’s t-test). (B) The band in the gel of the ChIP assay suggests that
the H3K27me3 site exists in the VDR gene promoter. Input DNA was used as a positive control; cell lysates incubated with non-relevant
rabbit IgG or cell lysate without antibody incubation were used as negative controls. (C) Real-time PCR of ChIP samples showed that
knockdown of EZH2 dramatically decreased the trimethylation level of H3K27 in the VDR promoter in HCT116 cells. n = 3, **p = 0.0097
(Student’s t-test). (D) Immunohistochemical analysis of consecutive human CRC tissue sections showed that higher levels of EZH2 nuclear
staining were observed in CRC samples than in normal colonic epithelial samples, and the expression of VDR showed the opposite trend
(original magnification ×400).
transcriptional activity of the EZH2 promoter was sig-
nificantly decreased after mutation of STAT3 binding
sites in the EZH2 promoter (Figure 6B). The data sug-
gest that STAT3 may activate the EZH2 promoter. In
a ChIP assay, we used a pair of primers covering a
region from −141 to 48 nt, containing four putative
STAT3 binding sites, in the EZH2 promoter. Figure 6D
shows that EZH2 genomic DNA was detectable in the
ChIP assay with STAT3 antibody incubated. ChIP real-
time PCR analysis demonstrated that overexpression
of STAT3 significantly increased the recruitment of
STAT3 to the EZH2 promoter (Figure 6E). The data
indicate that STAT3 may bind to the EZH2 promoter.
In addition, down-regulation of EZH2 blocked the
STAT3-induced increase in cell invasion in HCT116
cells (Figure 6F), indicating that EZH2 may participate
in STAT3-induced CRC cell invasion.
Expression of pSTAT3, STAT3, EZH2, and VDR in CRC
tissues
We also found an association between pSTAT3/VDR
expression and several known clinicopathological
features in CRC (Supplementary Tables 3 and 4). The
results suggest that pSTAT3 expression was positively
correlated with histological grade, vascular invasion,
and lymph node metastasis, and VDR expression
was negatively correlated with TNM stage, vascular
invasion, and lymph node metastasis. Furthermore, we
used univariate and multivariate analyses to analyse
whether the expression of EZH2 , VDR, and pSTAT3
was associated with metastasis (vascular invasion and
lymph node metastasis) in human CRC (Table 1). In
univariate analysis, EZH2 , VDR, and pSTAT3 were
significantly associated with vascular invasion and
lymph node metastasis, respectively; however, only
EZH2 was found to be significantly associated with
vascular invasion and lymph node metastasis in CRC
patients in multivariate analyses.
We found that 85.5% (71/83) of the CRC patients
who had low levels of VDR expression in their tumour
tissues exhibited up-regulation of EZH2 (p< 0.001).
The tumour tissues of 83.33% (65/78) of the patients
displaying high levels of pSTAT3 also expressed high
levels of EZH2 (p< 0.001). Furthermore, 81.93%
(68/83) of the patients with low levels of VDR in
their tumour tissues exhibited up-regulation of pSTAT3
(p< 0.001) (Supplementary Table 5).
Supplementary Table 6 shows the frequencies of
STAT3, pSTAT3, EZH2 , and VDR expression lev-
els in tumour tissues formed by CRC cells in which
STAT3 was down-regulated or up-regulated, com-
pared with control tumour tissues, in the nude mouse
xenograft model. High levels of pSTAT3 were found
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Figure 5. Effect of STAT3 on EZH2 and VDR expression in CRC cells. Western blot analysis data show that infection of STAT3 shRNA virus
dramatically inhibited the phosphorylation and expression of STAT3. STAT3 down-regulation significantly decreased the expression of EZH2
and increased the expression of VDR in SW1116 (A) and HCT116 cells (B). *p < 0.01 (Student’s t-test), compared with control shRNA virus.
Western blot analysis data show that the phosphorylation and expression of STAT3 were successfully increased after introducing STAT3
overexpression virus. EZH2 expression was significantly increased and VDR expression was decreased after the overexpression of STAT3 in
SW1116 (C) and HCT116 cells (D). n = 3, **p < 0.01 (Student’s t-test), compared with control virus. Real-time PCR and western blot data
show that introducing EZH2 shRNA virus significantly blocked STAT3-mediated VDR down-regulation in CRC cells (E, F). ANOVA, p < 0.05,
compared with control virus group; p < 0.05, compared with STAT3 overexpression virus group.
Copyright  2013 Pathological Society of Great Britain and Ireland. J Pathol 2013; 230: 277–290
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
286 Y-W Lin et al
Figure 6. The mechanism of STAT3-mediated EZH2 up-regulation in CRC cells. (A) STAT3 up-regulation dramatically increased the luciferase
activity of the EZH2 gene promoter, suggesting that STAT3 regulates the expression of EZH2 by modulating the transcriptional activity of
the EZH2 gene. n = 3, *p < 0.01 (Student’s t-test). (B) STAT3 binding sites in the EZH2 gene promoter. White and black triangles indicate
a wild-type or mutant sequence for STAT3 binding sites, respectively. WT = wild type; MT = mutant type of each STAT3 mutation binding
site. Mutation of STAT3 binding sites significantly decreased the transcriptional activity of the EZH2 promoter in the luciferase assay. n =
3, *p < 0.01 (Student’s t-test). (C) Bioinformatic analysis of STAT3 transcriptional factor binding sites in part of the EZH2 gene promoter
region. Numbers on the left-hand side indicate the locations upstream of the first base of the initial translation site. STAT3 binding sites
are highlighted, and the DNA sequence encompassed by two arrows was amplified in the ChIP assay. EZH2 DNA was detected in the
chromatin sample immunoprecipitated from HCT116 cells using an antibody against STAT3 (D), suggesting that STAT3 binds to the EZH2
promoter. (E) Real-time PCR of the ChIP samples showed that overexpression of STAT3 dramatically increased the binding efficiency of
STAT3 to the EZH2 promoter in CRC cells. ChIP assay real-time PCR was performed using GAPDH as a negative control for STAT3 binding.
n = 3, **p < 0.01 (Student’s t-test). (F) Transwell Matrigel invasion assays were performed in CRC cells infected with different viruses as
indicated. Cells were observed under a light microscope and photographed. Cells were counted from five random microscopic fields (200×)
per insert in triplicate. The migrated cell numbers were normalized to that of the control group. Data are shown as mean ± SD of three
separate experiments. n = 3, ANOVA, p < 0.01, compared with control virus plus control shRNA virus; p < 0.05, compared with STAT3
overexpression virus plus control shRNA virus. (G) Immunohistochemical analysis for pSTAT3 and EZH2 in consecutive human CRC tissue
sections. EZH2 and pSTAT3 were expressed at higher levels in CRC than in normal colonic epithelial samples, and the expression of VDR
showed the opposite trend. There was no significant difference in STAT3 expression in normal colonic epithelial samples or CRC tissues
(original magnification ×400).
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Table 1. Univariate and multivariate analyses using the Cox
proportional hazards model. EZH2 expression is significantly
associated with the metastasis (vascular invasion and lymph node
metastasis) of patients
Univariate analysis Multivariate analysis
No of
cases p value
Odds ratio
(95% CI) p value
Odds ratio
(95% CI)
pSTAT3
expression
High 78 0.01* 4.43 (1.91–10.28) 0.083 2.43 (0.89–6.60)
Low 51
EZH2
expression
High 86 0.01* 5.17 (2.06–12.99) 0.035* 3.09 (1.08–8.81)
Low 43
VDR
expression
High 46 0.045* 0.45 (0.20–1.06) 0.629 0.79 (0.30–2.06)
Low 83
CI = confidence intercal.
∗Statistically significant.
in STAT3-overexpressing tumours, and there was
almost no pSTAT3 staining in the STAT3-knockdown
tumours (Figure 7A). High levels of EZH2 expres-
sion were found in 87% of the STAT3-overexpressing
tumours and 7% of the STAT3-knockdown tumours
(Figure 7C). VDR was highly expressed in 79% of
the STAT3-knockdown tumours, and no VDR stain-
ing was detected in the STAT3-overexpressing tumours
(Figure 7D). Our data suggest that the expression
levels of pSTAT3 and EZH2 were significantly up-
regulated (chi-squared test, p< 0.001), while VDR
expression was significantly decreased (chi-squared
test, p< 0.001) in STAT3-overexpressing tumours.
Conversely, the expression of pSTAT3 and EZH2 was
significantly decreased (chi-squared test, p< 0.001),
while VDR expression was significantly increased in
the STAT3-knockdown tumours.
Discussion
As a transcriptional repressor, EZH2 is overexpressed
and has been regarded as a novel candidate onco-
gene in several types of human cancer [8,38,39]. It
has been reported that overexpression of EZH2 corre-
lates with increased invasion in several cancers [12,13].
However, the abnormalities of EZH2 and its underly-
ing mechanisms in the pathogenesis of CRC are not
fully understood. Four lines of argument suggest that
EZH2 plays an important role in CRC cell motility and
metastasis. First, the expression of EZH2 was signifi-
cantly increased in CRC cancer tissues and cell lines;
second, overexpression of EZH2 in CRC tissues may
increase the aggressiveness of the tumour; third, down-
regulation of EZH2 significantly decreased the cell
invasive ability and secretion of MMP2 and MMP9
in CRC cells; and finally, overexpression of EZH2
markedly increased the metastatic ability of CRC cells
and decreased overall survival in an in vivo model of
CRC metastasis. Conversely, down-regulation of EZH2
significantly decreased the metastatic ability of CRC
cells and increased overall survival in vivo.
Overexpression of EZH2 has been shown to down-
regulate the expression of E-cadherin by increasing the
H3K27 trimethylation level at the E-cadherin promoter
in prostate cancer cells [35]. An inverse correlation
has been demonstrated between EZH2 and runt-related
transcription factor 3 (RUNX3 ) gene expression in
gastric, breast, prostate, colon, and pancreatic cancer
cell lines, and EZH2 may bind to the RUNX3 gene
promoter and trimethylate the H3K27 mark [40].
EZH2 has also been reported to regulate cell migra-
tion/invasion via the regulation of E-cadherin and
transforming growth factor beta 1 (TGF-β1) expression
in ovarian carcinoma [33]. However, the molecular
mechanisms by which EZH2 regulates CRC cell migra-
tion/invasion remain unclear. Vitamin D and VDR
appear to mediate the prevention of tumour develop-
ment by inducing cellular differentiation and inhibiting
proliferation [41–43]. The expression of VDR is
repressed in high-grade and metastatic colorectal can-
cer [44]. We found that the mRNA and protein levels
of VDR were significantly up-regulated by knock-
down of EZH2 expression in CRC cells (Figure 3).
In luciferase assays, the transcriptional activity of
the VDR promoter was dramatically increased by
down-regulating EZH2 (Figures 4A–4C). These data
indicate that EZH2 may mediate VDR expression by
regulating the transcriptional activity of the VDR pro-
moter in CRC cells. Our result is consistent with the
report that EZH2 was predicted to regulate VDR gene
expression in germinal centre B cells [29]. Previous
immunohistochemical studies have shown a reduction
in the level of VDR in CRC samples [14,20,45]. We
found that high EZH2 expression in human clinical
specimens correlated with low expression of VDR
(Spearman’s correlation coefficient r = −0.65720;
p< 0.0001; Figure 4D). Furthermore, EZH2 -mediated
CRC cell invasion depended on the down-regulation
of VDR (Figures 3E and 3F). Down-regulation of
VDR due to overexpression of EZH2 may present one
pathway whereby EZH2 affects CRC cell invasion.
Previously we reported that the activation of
STAT3 may mediate human CRC tumourigenesis
and invasion [27], and STAT3 may directly induce
cell invasion and participate in the development of
resistance to chemotherapy and apoptosis during the
epithelial–mesenchymal transition (EMT) stage of
CRC progression [46]. As EZH2 was identified to
participate in the invasion of CRC cells in the present
study, we further examined whether STAT3 mediates
the expression of EZH2 in CRC cells. We found that
inhibition of STAT3 expression dramatically decreased
EZH2 expression and increased VDR expression
in CRC cells (Figures 5A and 5B). In addition,
overexpression of STAT3 significantly increased EZH2
expression and decreased VDR expression in CRC
cells (Figures 5C and 5D). These data demonstrate
Copyright  2013 Pathological Society of Great Britain and Ireland. J Pathol 2013; 230: 277–290
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
288 Y-W Lin et al
Figure 7. Expression levels of pSTAT3, STAT3, EZH2, and VDR in a nude mouse xenograft model of CRC. Immunohistochemical analysis
of pSTAT3, STAT3, EZH2, and VDR in xenograft tissue sections. STAT3 was successfully up-regulated or down-regulated after introducing
STAT3 shRNA and the STAT3 overexpression virus into nude mouse CRC cell model, respectively (A, B). The level of pSTAT3 and the
expression of EZH2 were significantly up-regulated in tumour samples with STAT3 overexpression (C), while the levels of pSTAT3 and EZH2
expression were significantly down-regulated in STAT3-knockdown tumour samples. The expression of VDR displayed an opposite trend
(D). (A–D) Original magnification: ×400.
Figure 8. Model for the possible mechanism of EZH2-induced
invasion in CRC and the regulatory mechanism of EZH2. Activation
of STAT3 in CRC cells leads to overexpression of EZH2, which results
in decreased expression of VDR and increased metastatic ability in
CRC cells.
that STAT3 may regulate EZH2 and VDR expression
in CRC cells. Moreover, EZH2 may play an important
role in STAT3-induced VDR down-regulation and
invasion in CRC cells (Figures 5E, 5F, and 6F). This
finding is consistent with bioinformatics predictions
that STAT3 may regulate EZH2 expression in prostate
cancer cells [28]. Furthermore, a positive transcrip-
tional effect of STAT3 binding the EZH2 promoter
was shown in this study via luciferase and ChIP
assays (Figures 6A–6E). However, VDR DNA was
not detected in the ChIP assay using an antibody
against STAT3 (data not shown), which suggests that
STAT3 may directly bind to the EZH2 promoter, but
not to the VDR promoter.
Our immunohistochemical data showed that pSTAT3
and EZH2 expression correlated positively with metas-
tasis in human CRC, compared with control (Figure 6G
and Table 1). In contrast, VDR expression was neg-
atively associated with metastasis in human CRC
(Figure 6G and Table 1). Moreover, a strong correlation
between human CRC metastasis and EZH2 expres-
sion was illustrated in the multivariate analyses. Highly
inverse correlations between the expression of EZH2
and pSTAT3 and that of VDR were also revealed in
the animal model.
In conclusion, we found that EZH2 may play an
important role in the process of tumour invasion in
CRC. Overexpression of EZH2 may result in H3K27
trimethylation of the VDR gene promoter, indicating
that VDR is a novel EZH2 target gene. EZH2 con-
tributes to CRC cell invasion by suppressing VDR
expression. Moreover, EZH2 overexpression can be
induced by activated STAT3. EZH2 may mediate the
STAT3-induced down-regulation of VDR and promote
cell invasion in CRC (Figure 8). These findings may
provide a potential target for treating aggressive col-
orectal cancers by inhibiting EZH2 .
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article.
Supplementary methods.
Figure S1. (A) Western blot analysis data show that introduction of lenti-EZH2 shRNA-1/2 virus successfully decreased EZH2 expression in
HCT116 CRC cells. (B) Western blot analysis data show that transduction of lenti-EZH2 overexpression virus remarkably increased the expression
of EZH2 in SW1116 CRC cells.
Figure S2. The concentrations of MMP2 and MMP9 were tested by ELISA in control or EZH2 shRNA virus-infected CRC cells.
Figure S3. Deletion variants of the EZH2 promoter pGL3-1220, 1020, 820, 620, 420, 220, and 20 were derived from pGL3-1220.
Table S1. Clinicopathological characteristics of EZH2 expression in patients with CRC.
Table S2. Haematoxylin and eosin staining of lungs to evaluate the presence of lung metastasis in nude mice.
Table S3. Clinicopathological characteristics of pSTAT3 expression in patients with CRC.
Table S4. Clinicopathological characteristics of VDR expression in patients with CRC.
Table S5. Correlation among the expression of EZH2, pSTAT3 or VDR in colorectal cancers.
Table S6. Immunohistochemical staining of 27 cases of subcutaneously transplanted tumour in nude mice to evaluate the expression of pSTAT3,
STAT3, EZH2, and VDR.
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